Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03263130 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03263130 · ClinicalTrials.gov record · last posted 2023-10-27

Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap

StatusRecruiting
PhaseNot specified
Started2017-01-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (\>15 pack years) with COPD, Emphysema, and Asthma-COPD Overlap with mild to severe expiratory airflow limitation. Treatment may include short and long acting inhaled beta2agonists, short and long acting inhaled muscarinic receptor antagonists, inhaled and or oral corticosteroid, oral antibiotic, supplemental oxygen, and PDE type 4 inhibitor. In some cases, the patient may have had a history of asthma preceding the development of COPD (Asthma COPD Overlap).

Amendment record 3 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 3 times since 2017-08-23; most recent amendment 2023-10-25. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT03263130
Lead Sponsor Gelb, Arthur F., M.D.
Conditions COPD, Emphysema, Asthma COPD Overlap, Emphysema
Enrollment 60 participants
Start Date 2017-01-01
Primary Completion 2027-01-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2023-10-27